← Eichor
Study identifier: NCT05639894 Synced from ClinicalTrials.gov · July 28, 2026
● Completed

Study of a Respiratory Syncytial Virus Candidate Encapsulated in a Lipid Nanoparticle Based Formulation in Adults Aged 18 to 50 Years and 60 Years and Older

Condition: Respiratory Syncytial Virus Immunization  ·  Sponsor: Sanofi Pasteur, a Sanofi Company

PhasePhase 1/Phase 2
Planned participants865
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersYes

About this study

Brief Summary of Stage 1: The purpose Stage 1 (Phase I/IIa) is to assess the safety and immunogenicity of a single intramuscular (IM) injection of 3 dose-levels of an Respiratory Syncytial Virus (RSV) vaccine candidate formulated with 2 different lipid nanoparticles (LNPs) in healthy adult participants aged between 18 to 50 years, and 60 years and older. The primary objectives of this stage are to assess the safety and immunogenicity profiles across the dose-level groups (low, medium, and high doses) with 2 LNPs. This stage will evaluate the safety and immunogenicity of a booster vaccination administered 12 months after the primary vaccination in a subset of the study population. Brief Summary of Stage 2: The study also also incorporates a Stage 2 (Phase IIa, dose-ranging design) that includes adults aged 60 years and older to assess the safety and immunogenicity of different doses of RSV vaccine encapsulated in one of the LNPs. In the Phase IIa dose-ranging stage, eligible participants will be randomly assigned in a 1:1:1 ratio to receive a single IM administration of RSV vaccine candidate doses, or placebo. Multiple safety analyses will be performed, minimally at D07 and D28. Additional analyses may be performed as data are available.

This description comes directly from the study's public registry record.

Talk to the study team

Contact details are listed per location below or on the registry record.

Always discuss trial participation with your own doctor first.

Locations (33)

Optimal Research Alabama Site Number : 8400032Huntsville, Alabama, United States
Aventiv Research Mesa Site Number : 8400020Mesa, Arizona, United States
CVS Health - Peoria Site Number : 8400042Peoria, Arizona, United States
CVS Health - Phoenix Site Number : 8400041Phoenix, Arizona, United States
Velocity Clinical Research - San Diego - ERN - PPDS Site Number : 8400010La Mesa, California, United States
Peninsula Research Associates Site Number : 8400013Rolling Hills Estates, California, United States
CVS Health - Thousand Oaks Site Number : 8400043Thousand Oaks, California, United States
Cenexel Research Centers of America Site Number : 8400024Hollywood, Florida, United States
Suncoast Research Associates, LLC Site Number : 8400003Miami, Florida, United States
Centricity Research - Georgia Site Number : 8400009Rincon, Georgia, United States
AES Peoria Site Number : 8400030Peoria, Illinois, United States
DM Clinical Research - Chicago Site Number : 8400027River Forest, Illinois, United States

+ 21 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05639894